Jinling Pharmaceutical Co Ltd (000919) - Total Assets
Based on the latest financial reports, Jinling Pharmaceutical Co Ltd (000919) holds total assets worth CN¥6.02 Billion CNY (≈ $881.50 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Jinling Pharmaceutical Co Ltd (000919) net assets for net asset value and shareholders' equity analysis.
Jinling Pharmaceutical Co Ltd - Total Assets Trend (1996–2024)
This chart illustrates how Jinling Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Jinling Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jinling Pharmaceutical Co Ltd's total assets of CN¥6.02 Billion consist of 59.4% current assets and 40.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 29.1% |
| Accounts Receivable | CN¥693.96 Million | 11.4% |
| Inventory | CN¥271.62 Million | 4.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥325.67 Million | 5.4% |
| Goodwill | CN¥62.42 Million | 1.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Jinling Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jinling Pharmaceutical Co Ltd (000919) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jinling Pharmaceutical Co Ltd's current assets represent 59.4% of total assets in 2024, a decrease from 65.3% in 1996.
- Cash Position: Cash and equivalents constituted 29.1% of total assets in 2024, up from 16.4% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 11.4% of total assets.
Jinling Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jinling Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Jinling Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.69 | 3.51 | 2.56 |
| Quick Ratio | 3.41 | 3.24 | 2.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.58 Billion | CN¥2.25 Billion | CN¥1.25 Billion |
Jinling Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jinling Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.22 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 33.8% |
| Total Assets | CN¥6.09 Billion |
| Market Capitalization | $672.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jinling Pharmaceutical Co Ltd's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jinling Pharmaceutical Co Ltd's assets grew by 33.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jinling Pharmaceutical Co Ltd (1996–2024)
The table below shows the annual total assets of Jinling Pharmaceutical Co Ltd from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.09 Billion ≈ $890.99 Million |
+33.81% |
| 2023-12-31 | CN¥4.55 Billion ≈ $665.88 Million |
+0.16% |
| 2022-12-31 | CN¥4.54 Billion ≈ $664.84 Million |
+2.15% |
| 2021-12-31 | CN¥4.45 Billion ≈ $650.83 Million |
+3.83% |
| 2020-12-31 | CN¥4.28 Billion ≈ $626.82 Million |
+3.01% |
| 2019-12-31 | CN¥4.16 Billion ≈ $608.50 Million |
+7.04% |
| 2018-12-31 | CN¥3.88 Billion ≈ $568.49 Million |
+0.73% |
| 2017-12-31 | CN¥3.86 Billion ≈ $564.40 Million |
-0.02% |
| 2016-12-31 | CN¥3.86 Billion ≈ $564.53 Million |
+0.20% |
| 2015-12-31 | CN¥3.85 Billion ≈ $563.41 Million |
+6.30% |
| 2014-12-31 | CN¥3.62 Billion ≈ $530.04 Million |
+9.62% |
| 2013-12-31 | CN¥3.30 Billion ≈ $483.54 Million |
+3.30% |
| 2012-12-31 | CN¥3.20 Billion ≈ $468.10 Million |
+8.13% |
| 2011-12-31 | CN¥2.96 Billion ≈ $432.89 Million |
+7.82% |
| 2010-12-31 | CN¥2.74 Billion ≈ $401.50 Million |
+11.74% |
| 2009-12-31 | CN¥2.46 Billion ≈ $359.32 Million |
+11.47% |
| 2008-12-31 | CN¥2.20 Billion ≈ $322.34 Million |
-6.91% |
| 2007-12-31 | CN¥2.37 Billion ≈ $346.26 Million |
+16.62% |
| 2006-12-31 | CN¥2.03 Billion ≈ $296.92 Million |
+10.10% |
| 2005-12-31 | CN¥1.84 Billion ≈ $269.67 Million |
+2.84% |
| 2004-12-31 | CN¥1.79 Billion ≈ $262.23 Million |
+9.59% |
| 2003-12-31 | CN¥1.64 Billion ≈ $239.28 Million |
+6.34% |
| 2002-12-31 | CN¥1.54 Billion ≈ $225.01 Million |
+8.57% |
| 2001-12-31 | CN¥1.42 Billion ≈ $207.25 Million |
+15.89% |
| 2000-12-31 | CN¥1.22 Billion ≈ $178.84 Million |
+4.35% |
| 1999-12-31 | CN¥1.17 Billion ≈ $171.39 Million |
+170.81% |
| 1998-12-31 | CN¥432.49 Million ≈ $63.29 Million |
+41.26% |
| 1997-12-31 | CN¥306.16 Million ≈ $44.80 Million |
+23.74% |
| 1996-12-31 | CN¥247.41 Million ≈ $36.20 Million |
-- |
About Jinling Pharmaceutical Co Ltd
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, an… Read more